A study found that SELENBP1 could inhibit angiogenesis by binding with Dll4 and antagonizing the Dll4/Notch1 signaling pathway in CRC, which made SELENBP1 a potential tumor suppressor [156]. This evidence concerns the gene DLL4 and colorectal carcinoma.